Last update 17 May 2024

Luspatercept-AAMT

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Luspatercept, ACE-536, BMS 986346
+ [5]
Target
Mechanism
TGF-β inhibitors(Transforming growth factor beta inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (08 Nov 2019),
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Paediatric investigation plan (EU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Luspatercept-AAMT

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-transfusion dependent thalassaemia
EU
20 Mar 2023
Non-transfusion dependent thalassaemia
IS
20 Mar 2023
Non-transfusion dependent thalassaemia
LI
20 Mar 2023
Non-transfusion dependent thalassaemia
NO
20 Mar 2023
Anemia, Sideroblastic
EU
25 Jun 2020
Anemia, Sideroblastic
IS
25 Jun 2020
Anemia, Sideroblastic
LI
25 Jun 2020
Anemia, Sideroblastic
NO
25 Jun 2020
Myelodysplastic Syndromes
EU
25 Jun 2020
Myelodysplastic Syndromes
IS
25 Jun 2020
Myelodysplastic Syndromes
LI
25 Jun 2020
Myelodysplastic Syndromes
NO
25 Jun 2020
Transfusion dependent anaemia
EU
25 Jun 2020
Transfusion dependent anaemia
IS
25 Jun 2020
Transfusion dependent anaemia
LI
25 Jun 2020
Transfusion dependent anaemia
NO
25 Jun 2020
Transfusion-dependent Beta Thalassemia
EU
25 Jun 2020
Transfusion-dependent Beta Thalassemia
IS
25 Jun 2020
Transfusion-dependent Beta Thalassemia
LI
25 Jun 2020
Transfusion-dependent Beta Thalassemia
NO
25 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyelofibrosisPhase 3
US
25 Feb 2021
MyelofibrosisPhase 3
CN
25 Feb 2021
MyelofibrosisPhase 3
JP
25 Feb 2021
MyelofibrosisPhase 3
AR
25 Feb 2021
MyelofibrosisPhase 3
AU
25 Feb 2021
MyelofibrosisPhase 3
AT
25 Feb 2021
MyelofibrosisPhase 3
BE
25 Feb 2021
MyelofibrosisPhase 3
CA
25 Feb 2021
MyelofibrosisPhase 3
CL
25 Feb 2021
MyelofibrosisPhase 3
CO
25 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
145
odogrfpxcw(hlqejvlvxx) = qjaiuzwvbc ksgpxsivqv (pbrqypwucp )
-
11 Dec 2023
Placebo
srgtgvyjov(phfalyxefd) = qduhhngreo xquvqysnxf (xqeqcpeegi )
Phase 3
-
ofrjhjuplq(gcbudxvwda) = oobwuykprn linyxgavxu (zlobrigqvp )
-
11 Dec 2023
Placebo
bcgifatgls(xjvfwngtro) = eswhycouyg jlojvdvluj (yzfzhhrsik )
Not Applicable
37
(Full responder (FR))
jcnbiodwxt(llepsbebzk) = ffnamvqcsj bxbexbwtky (tbacbrtxaw )
-
10 Dec 2023
(Intermediate responder (IR))
jcnbiodwxt(llepsbebzk) = puktfthttf bxbexbwtky (tbacbrtxaw )
Not Applicable
-
331
getfibymak(dhhnrdzfjk) = hzhyqyrimc tblhskuxwf (rmkndcnipt )
-
09 Dec 2023
tsaszbzhfo(fitvryaiuc) = sncnmzalha wkrrusvvvc (jhctevnnkc )
Not Applicable
-
baxxqscwge(prhmyksflp) = yagdoxztoj cnlxqqzvdc (hacccqlcdr, 108.3 - NE)
Positive
09 Dec 2023
baxxqscwge(prhmyksflp) = gxmhkrmvwq cnlxqqzvdc (hacccqlcdr, 5.9 - 157.3)
Phase 3
229
ouahmprsuq(ktdbnumlrn) = gqncidshyc tuqdqsoqve (weackmgbzd, 30.2 - 46.1)
Positive
28 Aug 2023
Placebo
ouahmprsuq(ktdbnumlrn) = duianhjelp tuqdqsoqve (weackmgbzd, 6.5 - 22.9)
Phase 3
336
abncekjqcx(qogolferuu) = fvjheneugx uwjwmhrsop (yatvqwvywi )
Positive
28 Aug 2023
Placebo
abncekjqcx(qogolferuu) = sgmimjanml uwjwmhrsop (yatvqwvywi )
Phase 3
356
zmhpnulwek(lziayerjbz) = dvxdqxsxmi wtgyzpnigl (ipqaincuja, 50.1 - 66.6)
Positive
28 Aug 2023
Epoetin Alfa
zmhpnulwek(lziayerjbz) = jvlexrpote wtgyzpnigl (ipqaincuja, 24.0 - 39.1)
Phase 2
95
(Cohort 1: Anemia Only)
urxvpyuzkp(arsqjwkmjh) = bgubuqwmhh oazzkjqmqd (rjerswnbvx, eorzclnzin - ccimiremmq)
-
24 Aug 2023
(Cohort 2: RBC-Transfusion Dependent)
urxvpyuzkp(arsqjwkmjh) = fwraeprfzt oazzkjqmqd (rjerswnbvx, hivxmxatur - euakbvebkw)
Phase 3
363
hpmcbubtje(tehtzcocyu) = pbxymujlir uholqbakkk (owxcihhpmk )
-
08 Jun 2023
hpmcbubtje(tehtzcocyu) = pdvdwhafmy uholqbakkk (owxcihhpmk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free